This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called amlitelimab for people with atopic dermatitis, which is a type of eczema that causes itchy and inflamed skin. The study is designed for participants who have already taken part in previous trials involving amlitelimab for moderate to severe atopic dermatitis. Amlitelimab is administered as a solution for injection under the skin, known as a subcutaneous injection. The purpose of this study is to gather more information about how safe and tolerable amlitelimab is when used over a longer period.

Participants in this study will continue to receive amlitelimab and will be monitored for any side effects or changes in their condition. The study will also compare amlitelimab with other treatments, including agents for dermatitis that do not contain steroids, glucocorticoids, and plain corticosteroids. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the effects of amlitelimab more clearly. The study will track the percentage of participants who experience any adverse events, which are unwanted effects that occur during treatment.

The trial will last for several years, allowing researchers to observe the long-term impact of amlitelimab on atopic dermatitis. Participants will have regular visits to assess their skin condition and overall health. The study aims to provide valuable insights into how amlitelimab can help manage atopic dermatitis over time, potentially improving the quality of life for those affected by this chronic skin condition.